{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:52:59Z","timestamp":1793656379997,"version":"4.5.1"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>The global rise in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) represents a critical and intertwined public health challenge. Both conditions share overlapping mechanisms, such as insulin resistance, lipid toxicity, chronic inflammation, and mitochondrial dysfunction, that drive disease progression and worsen outcomes. This review synthesizes emerging evidence on the bidirectional relationship between T2DM and MASLD, with a specific focus on underrecognized clinical intersections, including hepatogenous diabetes and the role of subclinical liver injury in diabetic patients. Unlike prior reviews, it emphasizes mechanistic links involving advanced glycation end products, cytokine dysregulation, and microvascular dysfunction, highlighting their implications for both hepatic and extrahepatic complications. We summarize epidemiological trends, outline gaps in current screening practices, and assess therapeutic strategies ranging from glycemic control and hepatoprotective antidiabetic agents to liver-directed interventions. Key takeaways for clinicians include the importance of early, integrated liver fibrosis assessment in diabetic care and the need for multidisciplinary approaches to reduce risks of cirrhosis, hepatocellular carcinoma, and mortality. By bridging pathophysiological insights with practical screening and treatment considerations, this review aims to guide more proactive and coordinated management of patients affected by T2DM and MASLD.<\/jats:p>","DOI":"10.1097\/ms9.0000000000004012","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:00:16Z","timestamp":1760605216000},"page":"8418-8425","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Diabetes and liver cirrhosis: shared pathways and clinical implications \u2013 a narrative review"],"prefix":"10.1097","volume":"87","author":[{"given":"Anmol","family":"Mohan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Carle Foundation Hospital, Urbana, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zim Warda","family":"Hasan","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science, School of Medicine, West Virginia University, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetvi Gordhan","family":"Galani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Bukovinian State Medical University, Chernivtsi, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahniat","family":"Afroze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dr. VRK Women\u2019s Medical College, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukash Khan","family":"Niazi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sargodha Medical College, Sargodha, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Alfaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Khartoum, Khartoum, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atika","family":"Shahzadi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, CMH Kharian Medical College, Kharian, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka Mohan","family":"Lal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ziauddin University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-7800","authenticated-orcid":false,"given":"Hasibullah","family":"Aminpoor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Kabul University of Medical Sciences, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-3849","authenticated-orcid":false,"given":"Hasiba","family":"Karimi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikash","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Brooklyn Hospital Center, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Tejwaney","sequence":"additional","affiliation":[{"name":"Department of internal medicine, Valley Health System, Ridgewood, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarwan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"R1-20260319","first-page":"10\u201397","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction\u2013associated steatotic liver disease","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"R2-20260319","doi-asserted-by":"crossref","first-page":"431\u201339","DOI":"10.1080\/17474124.2024.2388790","article-title":"Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist","volume":"18","author":"Yeh","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R3-20260319","doi-asserted-by":"crossref","first-page":"111650","DOI":"10.1016\/j.diabres.2024.111650","article-title":"Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: bi-directional opportunities to multiply preventive strategies","volume":"221","author":"Yasin","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"R4-20260319","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/1573399819666230216112032","article-title":"Common pathogenetic pathways of non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"19","author":"Giannopoulos","year":"2023","journal-title":"Curr Diabetes Rev"},{"key":"R5-20260319","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem Sci"},{"key":"R6-20260319","first-page":"216\u201326","article-title":"Emerging concepts in the pathophysiology of type 2 diabetes mellitus","volume":"76","author":"Surampudi","year":"2009","journal-title":"Mount Sinai J Med, NY"},{"key":"R7-20260319","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R8-20260319","first-page":"585\u2013618","article-title":"Pathophysiology and pharmacological treatment of insulin resistance","volume":"21","author":"Matthaei","year":"2000","journal-title":"Endocr Rev"},{"key":"R9-20260319","doi-asserted-by":"crossref","first-page":"46\u201357","DOI":"10.5897\/JPAP2013.0001","article-title":"The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus","volume":"4","author":"Ozougwu","year":"2013","journal-title":"J Physiol Pathophysiol"},{"key":"R10-20260319","doi-asserted-by":"crossref","first-page":"895\u2013910","DOI":"10.1016\/j.jhep.2024.06.016","article-title":"Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation","volume":"81","author":"Taru","year":"2024","journal-title":"J Hepatol"},{"key":"R11-20260319","first-page":"245","article-title":"Chronic hepatic failure","volume":"15","author":"Erstad","journal-title":"DeckerMed Surg"},{"key":"R12-20260319","first-page":"1\u201319","article-title":"Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2018","journal-title":"Mol Aspects Med"},{"key":"R13-20260319","doi-asserted-by":"crossref","first-page":"1234\u201341","DOI":"10.1136\/gutjnl-2012-302826","article-title":"Beyond scoring: a modern interpretation of disease progression in chronic liver disease","volume":"62","author":"Rosselli","year":"2013","journal-title":"Gut"},{"key":"R14-20260319","doi-asserted-by":"crossref","first-page":"947\u201368","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab"},{"key":"R15-20260319","doi-asserted-by":"crossref","first-page":"170\u201375","DOI":"10.1111\/j.2040-1124.2011.00111.x","article-title":"Molecular mechanisms involved in hepatic steatosis and insulin resistance","volume":"2","author":"Matsuzaka","year":"2011","journal-title":"J Diabetes Investig"},{"key":"R16-20260319","doi-asserted-by":"crossref","first-page":"434\u201341","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J Gastroenterol"},{"key":"R18-20260319","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression From NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"R19-20260319","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/ijms19072034","article-title":"New aspects of lipotoxicity in nonalcoholic steatohepatitis","volume":"19","author":"Mendez-Sanchez","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R20-20260319","doi-asserted-by":"crossref","first-page":"84\u201395","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"R21-20260319","doi-asserted-by":"crossref","first-page":"21\u201333","DOI":"10.1111\/nyas.15184","article-title":"Metabolic dysfunction-associated liver disease and diabetes: matrix remodeling, fibrosis, and therapeutic implications","volume":"1538","author":"Fan","year":"2024","journal-title":"Ann N Y Acad Sci"},{"key":"R22-20260319","doi-asserted-by":"crossref","first-page":"e0153118","DOI":"10.1371\/journal.pone.0153118","article-title":"Characterization of the MMP\/TIMP imbalance and collagen production induced by IL-1\u03b2 or TNF-\u03b1 release from human hepatic stellate cells","volume":"11","author":"Robert","year":"2016","journal-title":"PLoS ONE"},{"key":"R24-20260319","first-page":"920613","article-title":"Cytokines and diabetes research","volume":"2","author":"Xiao","year":"2014","journal-title":"J Diabetes Res"},{"key":"R25-20260319","doi-asserted-by":"crossref","first-page":"369\u201376","DOI":"10.1111\/jgh.12042","article-title":"Advanced glycation end products augment experimental hepatic fibrosis","volume":"28","author":"Goodwin","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R26-20260319","doi-asserted-by":"crossref","first-page":"389\u201397","DOI":"10.1016\/j.jhep.2009.12.007","article-title":"Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells","volume":"52","author":"Guimar\u00e3es","year":"2010","journal-title":"J Hepatol"},{"key":"R27-20260319","doi-asserted-by":"crossref","first-page":"19846\u201366","DOI":"10.3390\/ijms141019846","article-title":"Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products","volume":"14","author":"Santos","year":"2013","journal-title":"Int J Mol Sci"},{"key":"R28-20260319","doi-asserted-by":"crossref","first-page":"112\u201317","DOI":"10.1248\/bpb.b20-00708","article-title":"Suppression of hepatic stellate cell death by toxic advanced glycation end-products","volume":"44","author":"Takino","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"R29-20260319","doi-asserted-by":"crossref","first-page":"29\u201355","DOI":"10.1210\/endrev\/bnaa025","article-title":"Microvascular dysfunction in diabetes mellitus and cardiometabolic disease","volume":"42","author":"Horton","year":"2021","journal-title":"Endocr Rev"},{"key":"R30-20260319","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3390\/diagnostics14242830","article-title":"Diagnosis, pathophysiology and management of microvascular dysfunction in diabetes mellitus","volume":"14","author":"Jan","year":"2024","journal-title":"Diagnostics"},{"key":"R31-20260319","doi-asserted-by":"crossref","first-page":"721\u201326","DOI":"10.2337\/diab.44.7.721","article-title":"Microvascular function in human diabetes: a physiological perspective","volume":"44","author":"Tooke","year":"1995","journal-title":"Diabetes"},{"key":"R32-20260319","doi-asserted-by":"crossref","first-page":"1\u20137","DOI":"10.1016\/j.vph.2017.01.004","article-title":"Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches","volume":"90","author":"Madonna","year":"2017","journal-title":"Vascul Pharmacol"},{"key":"R33-20260319","doi-asserted-by":"crossref","first-page":"111648","DOI":"10.1016\/j.diabres.2024.111648","article-title":"Epidemiology of NAFLD - Focus on diabetes","volume":"210","author":"Younossi","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"R34-20260319","doi-asserted-by":"crossref","first-page":"2231\u201338","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-20260319","doi-asserted-by":"crossref","first-page":"124\u201331","DOI":"10.1053\/j.gastro.2010.09.038","article-title":"Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study","volume":"140","author":"Williams","year":"2011","journal-title":"Gastroenterology"},{"key":"R36-20260319","first-page":"58\u201362","article-title":"Prevalence of non-alcoholic steatohepatitis. Comparative study with diabetic patients","volume":"65","author":"Bernal-Reyes","year":"2000","journal-title":"Rev de Gastroenterologia de Mex"},{"key":"R37-20260319","first-page":"5308308","article-title":"Diabetes mellitus and risk of hepatic fibrosis\/cirrhosis","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"R38-20260319","doi-asserted-by":"crossref","first-page":"280\u201388","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management","volume":"15","author":"Garc\u00eda-Compe\u00e1n","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R39-20260319","doi-asserted-by":"crossref","first-page":"1639\u201348","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"key":"R40-20260319","first-page":"9\u201316","article-title":"Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases","volume":"3","author":"Raff","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"R41-20260319","first-page":"15\u201321","article-title":"Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis","volume":"Suppl 1","author":"Petrides","year":"1999","journal-title":"Z Gastroenterol"},{"key":"R42-20260319","doi-asserted-by":"crossref","first-page":"99\u2013107","DOI":"10.4254\/wjh.v3.i5.99","article-title":"Insulin resistance and chronic liver disease","volume":"3","author":"Kawaguchi","year":"2011","journal-title":"World J Hepatol"},{"key":"R43-20260319","first-page":"248\u201352","article-title":"NAFLD et NASH au cours du diab\u00e8te: donn\u00e9es \u00e9pid\u00e9miologiques, cliniques et pronostiques","volume":"7","author":"B\u00e9land-Bonenfant","year":"2023","journal-title":"Med Des Mal M\u00e9taboliques"},{"key":"R44-20260319","first-page":"368\u201369","article-title":"Physiopathologie du diab\u00e8te. M\u00e9canismes d\u2019une pand\u00e9mie silencieuse","volume":"17","author":"Grimaldi","year":"2023","journal-title":"M\u00e9d Des Mal M\u00e9taboliques"},{"key":"R45-20260319","doi-asserted-by":"crossref","first-page":"8377\u201392","DOI":"10.3748\/wjg.v20.i26.8377","article-title":"Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment","volume":"20","author":"Leite","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R46-20260319","doi-asserted-by":"crossref","first-page":"172\u201377","DOI":"10.1016\/j.amjmed.2023.10.002","article-title":"Underrecognition and suboptimal quality of care for nonalcoholic fatty liver disease cirrhosis in primary care patients with diabetes mellitus","volume":"137","author":"Chu","year":"2024","journal-title":"Am J Med"},{"key":"R47-20260319","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.jhepr.2021.100293","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour","year":"2021","journal-title":"JHEP Reports"},{"key":"R48-20260319","first-page":"158\u201367","article-title":"Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting","volume":"5","author":"Vieira","year":"2021","journal-title":"Hepatol Commun"},{"key":"R49-20260319","doi-asserted-by":"crossref","first-page":"399\u2013406","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"R50-20260319","doi-asserted-by":"crossref","first-page":"108358","DOI":"10.1016\/j.diabres.2020.108358","article-title":"Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: insights from NHANES 2005-2016","volume":"167","author":"Ciardullo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"R51-20260319","doi-asserted-by":"crossref","first-page":"173\u201386","DOI":"10.1007\/s11684-015-0384-0","article-title":"Metformin and metabolic diseases: a focus on hepatic aspects","volume":"9","author":"Zheng","year":"2015","journal-title":"Front Med"},{"key":"R52-20260319","doi-asserted-by":"crossref","first-page":"1\u20137","DOI":"10.1016\/j.ejphar.2019.02.004","article-title":"Hepatoprotective activity of metformin: a new mission for an old drug?","volume":"850","author":"Iranshahy","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"R53-20260319","first-page":"403\u201314","article-title":"Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders","volume":"22","author":"Yaribeygi","year":"2023","journal-title":"EXCLI J"},{"key":"R54-20260319","doi-asserted-by":"crossref","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!","volume":"101","author":"Ranjbar","year":"2019","journal-title":"Metabolism"},{"key":"R56-20260319","doi-asserted-by":"crossref","first-page":"763\u201367","DOI":"10.1097\/MPA.0000000000001569","article-title":"Effectiveness of liver-directed therapy for the management of intractable hypoglycemia in metastatic insulinoma","volume":"49","author":"Habibollahi","year":"2020","journal-title":"Pancreas"},{"key":"R57-20260319","doi-asserted-by":"crossref","first-page":"281\u201389","DOI":"10.15403\/jgld.2014.1121.273.daa","article-title":"Impact of Direct Acting Antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C","volume":"27","author":"Weidner","year":"2018","journal-title":"JGLD"},{"key":"R58-20260319","doi-asserted-by":"crossref","first-page":"1461\u201379","DOI":"10.1007\/s00125-021-05442-2","article-title":"Liver-targeting drugs and their effect on blood glucose and hepatic lipids","volume":"64","author":"Gastaldelli","year":"2021","journal-title":"Diabetologia"},{"key":"R59-20260319","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.12566","article-title":"Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control","author":"Bloomgarden","year":"2017","journal-title":"Journal of Diabetes"},{"key":"R60-20260319","doi-asserted-by":"crossref","first-page":"1096\u2013108","DOI":"10.1016\/j.metabol.2016.01.001","article-title":"Non-alcoholic fatty liver disease and diabetes","volume":"65","author":"Hazlehurst","year":"2016","journal-title":"Metabolism"},{"key":"R61-20260319","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31806","article-title":"Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"R62-20260319","doi-asserted-by":"crossref","first-page":"1291\u2013306","DOI":"10.4254\/wjh.v14.i7.1291","article-title":"Hepatogenous diabetes: Knowledge, evidence, and skepticism","volume":"14","author":"Kumar","year":"2022","journal-title":"World J Hepatol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:04:11Z","timestamp":1773936251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004012","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"2025-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}